Fetal and neonatal alloimmune thrombocytopenia
Prevalence estimates on Rare Medical Network websites are calculated based on data available from numerous sources, including US and European government statistics, the NIH, Orphanet, and published epidemiologic studies. Rare disease population data is recognized to be highly variable, and based on a wide variety of source data and methodologies, so the prevalence data on this site should be assumed to be estimated and cannot be considered to be absolutely correct.
Age of Onset
Autosomal dominant ?A pathogenic variant in only one gene copy in each cell is sufficient to cause an autosomal dominant disease
Autosomal recessive ?Pathogenic variants in both copies of each gene of the chromosome are needed to cause an autosomal recessive disease and observe the mutant phenotype
X-linked dominant ?X-linked dominant inheritance, sometimes referred to as X-linked dominance, is a mode of genetic inheritance by which a dominant gene is carried on the X chromosome.
X-linked recessive ?Pathogenic variants in both copies of a gene on the X chromosome cause an X-linked recessive disorder
Mitochondrial or multigenic ?Mitochondrial genetic disorders can be caused by changes (mutations) in either the mitochondrial DNA or nuclear DNA that lead to dysfunction of the mitochondria and inadequate production of energy.
Multigenic or multifactor ?Inheritance involving many factors, of which at least one is genetic but none is of overwhelming importance, as in the causation of a disease by multiple genetic and environmental factors.
Other Names (AKA)
Fetal and neonatal alloimmune
This table lists symptoms that people with this disease may have. For most diseases, symptoms will vary from person to person. People with the same disease may not have all the symptoms listed. This information comes from a database called the Human Phenotype Ontology (HPO) . The HPO collects information on symptoms that have been described in medical resources. The HPO is updated regularly. Use the HPO ID to access more in-depth information about a symptom.
|Medical Terms||Other Names||
|100% of people have these symptoms|
|30%-79% of people have these symptoms|
|5%-29% of people have these symptoms|
Blood in urine
|1%-4% of people have these symptoms|
|Bilateral sensorineural hearing impairment||0008619|
Management for pregnancies determined to be at risk remains controversial but may include a planned delivery and maternal avoidance of nonsteroidal anti-inflammatory drugs (NSAIDS) and aspirin during pregnancy. Management strategies have also included maternal intravenous immunoglobulin (IVIG) or maternal steroids and more invasive procedures such as fetal blood sampling and fetal platelet transfusions. The less invasive approach is currently favored.
Management of the affected infant after birth depends on the specific signs and symptoms but may include periodic ultrasounds of the brain to check for bleeding,
These resources provide more information about this condition or associated symptoms. The in-depth resources contain medical and scientific language that may be hard to understand. You may want to review these resources with a medical professional.
- The Monarch Initiative brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch’s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.
- Orphanet is a European reference portal for information on rare diseases and orphan drugs. Access to this database is free of charge.
- PubMed is a searchable database of medical literature and lists journal articles that discuss Fetal and neonatal alloimmune thrombocytopenia. Click on the link to view a sample search on this topic.
- Moise, Kenneth. What is NAIT. naitbabies.org. 2010; https://www.naitbabies.org/resources/what-is-nait/.
- Espinoza JP, Caradeux J, Norwitz ER, Illanes SE.. Fetal and Neonatal Alloimmune Thrombocytopenia. Reviews in Obstetrics and Gynecology. 2013; 6(1):e15-e21. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3651544/.
- Peterson JA, McFarland JG, Curtis BR, Aster RH. Neonatal alloimmune thrombocytopenia: pathogenesis, diagnosis and management. British journal of haematology. 2013; 161(1):3-14. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895911/.
- Paidas, Michael. Neonatal alloimmune thrombocytopenia: Parental evaluation and pregnancy management. UpToDate. March 17, 2017; https://www.uptodate.com/contents/neonatal-alloimmune-thrombocytopenia-parental-evaluation-and-pregnancy-management.
- Winkelhorst D., Murphy MF, Greinacher A, et al.. Antenatal management in fetal and neonatal alloimmune thrombocytopenia: a systematic review. Blood. March, 2017; 129(11):https://www.bloodjournal.org/content/bloodjournal/129/11/1538.full.pdf.